Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
9/10
Growth Score
7/10
Valuation Score
6/10
Momentum Score
9/10
₹24,406 Cr
14.91
3.74
45.38
0
29.36 %
--
0.7 %
364.11
92
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| 67.95 | -11.37 | 14.33 | 56.08 | 14.71 | 18.89 | 16.20 |
|
BSE Healthcare
| 38.74 | 1.81 | 17.79 | 53.60 | 18.58 | 28.78 | 11.84 |
|
BSE Mid Cap
| 31.28 | -1.40 | 4.22 | 49.54 | 24.23 | 28.35 | 17.66 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| 44.46 | -37.92 | -6.48 | 55.58 | -14.53 | -31.05 | 65.91 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 | 48.13 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
₹24,405.51 Cr
₹4,220.90 Cr
₹1,636.50 Cr
₹1,396.40 Cr
₹363.20 Cr
49.71%
High
₹724.20 - 1,639.00
₹2.00
17,91,09,870
NSE: NATCOPHARM, BSE: 524816
Hyderabad, Telangana
www.natcopharma.co.in
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company offers formulations in various therapeutic areas, including cancers of blood,... liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. It also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Additionally, it offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Read more
The total asset value of Natco Pharma Ltd stood at ₹ 6,906 Cr as on 30-Jun-24
The share price of Natco Pharma Ltd is ₹1,362.70 (NSE) and ₹1,362.60 (BSE) as of 03-Oct-2024 IST. Natco Pharma Ltd has given a return of 14.71% in the last 3 years.
Natco Pharma Ltd has a market capitalisation of ₹ 24,406 Cr as on 03-Oct-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Natco Pharma Ltd is 3.74 times as on 03-Oct-2024, a 25% discount to its peers’ median range of 5.00 times.
The P/E ratio of Natco Pharma Ltd is 14.91 times as on 03-Oct-2024, a 67% discount to its peers’ median range of 45.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Natco Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Natco Pharma Ltd.
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. It also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Additionally, it offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
The prominent promoters of Natco Pharma Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
V C NANNAPANENI |
15.66%
|
|
TIME CAP PHARMA LABS PRIVATE LIMITED |
9.59%
|
|
VENKATA SATYA SWATHI KANTAMANI |
8.92%
|
|
NATSOFT INFORMATION SYSTEMS PVT LTD |
8.81%
|
The chairman of the company is V C Nannapaneni, and the managing director is V C Nannapaneni.
There is no promoter pledging in Natco Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
47,550
|
|
|
35,631
|
|
|
29,577
|
|
|
29,517
|
| Natco Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
29.36
|
|
Operating margin(%)
|
43.61
|
|
Net Margin(%)
|
37.39
|
|
Dividend yield(%)
|
0.7
|
Yes, TTM profit after tax of Natco Pharma Ltd was ₹1,637 Cr.
₹-37.60
